Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV6 | Q9H1D0 | 3/20 | 0.33 |
| ▸ | ORAI1 | Q96D31 | 2/20 | 0.33 |
| ▸ | ORAI2 | Q96SN7 | 2/20 | 0.33 |
| ▸ | ORAI3 | Q9BRQ5 | 2/20 | 0.33 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2406507 | 0.73 | TRPV6 (0.54) | TRPV6ORAI1ORAI2ORAI3PCSK9 | |
| SCHEMBL16632985 | 0.64 | GPR3 (0.54) | TRPV6ORAI1ORAI2ORAI3PCSK9 | |
| SCHEMBL20401819 | 0.60 | GPR3 (0.39) | — | |
| SCHEMBL2412647 | 0.60 | TRPV6 (0.93) | TRPV6ORAI1ORAI2ORAI3PCSK9 | |
| SCHEMBL2406124 | 0.58 | TRPV6 (0.78) | TRPV6ORAI1ORAI2ORAI3PCSK9 | |
| Diphenyl Borinic Acid SCHEMBL40601 | 0.58 | TRPV6 (1.00) | TRPV6ORAI1ORAI2ORAI3PCSK9 | |
| SCHEMBL24426308 | 0.57 | GPR3 (0.43) | — | |
| SCHEMBL2406379 | 0.56 | TRPV6 (0.82) | TRPV6ORAI1ORAI2ORAI3PCSK9 | |
| Diphenyl Borinic Acid SCHEMBL28080639 | 0.56 | TRPV6 (0.93) | TRPV6ORAI1ORAI2ORAI3PCSK9 | |
| SCHEMBL17698481 | 0.55 | TRPV6 (0.70) | TRPV6ORAI1ORAI2ORAI3PCSK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8853424-B2 | Protein cross-linking inhibitor | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2014-10-07 | — | — | US | disclosed |
| US-20110212919-A1 | PROTEIN CROSS-LINKING INHIBITOR | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2011-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212919-A1 | PROTEIN CROSS-LINKING INHIBITOR | BAZ2B, PRMT1, BRIX1 | TRPV6 4868/4885ORAI1 4605/4885ORAI2 3906/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.